Status:
RECRUITING
Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery
Lead Sponsor:
Saint Petersburg State University, Russia
Conditions:
Thoracic Surgery
Heart Diseases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinol...
Detailed Description
Routine use of fibrinolysis inhibitors is strongly recommended in cardiac surgery (recommendation level 1A). However, despite numerous studies on the pharmacodynamics and clinical effects of these dru...
Eligibility Criteria
Inclusion
- A hospital that performs a minimum of 250 open heart interventions per year.
- Consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol).
Exclusion
- Hospital does not meet inclusion criteria
Key Trial Info
Start Date :
August 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
1373 Patients enrolled
Trial Details
Trial ID
NCT06493227
Start Date
August 1 2024
End Date
June 1 2026
Last Update
January 27 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiac surgery department, Saint-Petersburg state university hospital
Saint Petersburg, Russia
2
St. Petersburg State University Hospital
Saint Petersburg, Russia